San Diego, CA (PRWEB) April 19, 2013
Resource4thePeople announced today a consumer update of the consolidated federal courts litigation involving allegations that the use of the popular blood thinner Pradaxa may cause internal bleeding problems.
The federal judge overseeing this litigation* has scheduled a special hearing for April 15 at which lawyers for the plaintiffs who have filed claims in this multidistrict litigation and attorneys for Pradaxa will update the judge on the status of the litigation.
The claims before the judge in the U.S. District Court in the Southern District of Illinois involve common allegations that they suffered serious internal bleeding problems and are seeking compensation for the medical costs and other expenses they allege they have incurred as a result of using Pradaxa to protect against strokes and heart attacks.
Resource4thePeople is also informing consumers who may be affected by this litigation that the court docket shows that the number of Pradaxa lawsuits claiming internal bleeding problems has climbed to at least 260 cases.**
Although the first trials in the consolidated cases are not scheduled until September of 2014 there are numerous hearings such as this in which legal questions about pre-trial evidence-gathering and other issues are litigated.
Resource4thePeople also is informing consumers that its attorneys are now accepting cases from consumers who allegedly may have suffered serious health problems as a result of their use of the popular blood thinner Pradaxa.
“Our lawyers are now available for free consultations in which those consumers who have been contacting us about their legal rights can be informed about their eligibility to seek compensation over alleged internal bleeding problems involving the use of Pradaxa,” said Resource4thePeople.
“This response comes in reaction to the increasing number of inquiries that we have been receiving from consumers concerned about the possibility of serious health side effects such as internal bleeding that may have occurred as a result of using the medication Pradaxa."
Resource4thePeople also will continue to update consumers about the important developments in the Pradaxa multidistrict litigation* in which cases from across the country have been consolidated.
"We will be informing consumers about whether they may be eligible to join in this multidistrict litigation which is now under the supervision of a single judge in Illinois," said Resource4thePeople.
The Pradaxa plaintiffs, according to the court file,* are seeking compensation for wrongful deaths, medical costs, pain and suffering and other expenses if they can prove their claims.
Multidistrict litigations are so designated by the federal court system when a large number of cases involving similar allegations are brought under the supervision of a single judge for pre-trial evidence gathering and other legal procedures.
That judge may set bellwether trials, in which both plaintiffs' and defendants' lawyers test the strengths and weaknesses of their cases, and may also eventually designated the litigation as a massive class-action.
"One of the inquiries we are repeatedly receiving is whether it is too late to file a lawsuit that could be part of this multi-district litigation," said Resource4thePeople spokesman William Howell. "The answer, in the overwhelming number of cases, is no."
"The federal judge in the case has not issued any order prohibiting additional claims being filed and, in his most recent ruling, found that plaintiffs' lawyers will be granted access to documents they were seeking, which means there will still be additional time before any trial is held," Howell said.
The current litigation before U.S. District Court Judge David R. Herndon involves allegations, according to the complaints, that Pradaxa can cause serious internal bleeding problems which can lead to heart attacks and brain hemorrhages.*
Pradaxa’s manufacturer, Boehringer Ingelheim, has denied the claims that have been filed against them in the litigation, including allegations contained in the complaints that the company was negligent by failing to adequately warn health care professionals and patients about bleeding side effects.*
According to allegations in the Pradaxa multi-district litigation, the drug was approved by the FDA in 2010 as an improvement over another blood-thinner, warfarin, for patients vulnerable to atrial fibrillation.
Plaintiffs in the Pradaxa multi-district litigation are claiming that in cases of internal bleeding there is an antidote for warfarin but there is no antidote for Pradaxa and that in some cases deaths have occurred.
There are currently over 150 lawsuits according to Bloomberg News,*** which also recently reported that Pradaxa “has been linked to more than 500 U.S. deaths over a two-year period.”
Bloomberg also reported that “Concerns about Pradaxa’s safety surfaced soon after U.S. doctors began prescribing it. FDA officials said they received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011.”***
Resource4thePeople also is advising consumers who may have been or are being treated with Pradaxa that the FDA recently issued a Drug Safety Communication warning that the medication should not be used in patients with mechanical prosthetic heart valves.*****
In the communication the FDA also noted a previously released Drug Safety Communication about the risk of serious bleeding associated with the use of Pradaxa in patients with non-valvular atrial fibrillation, the population for which the drug is approved.
- MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, U.S. District Court, Southern District of Illinois